An Australian-first trial using medicinal cannabis to treat returned servicemen and women suffering from post-traumatic stress disorder (PTSD) has launched targeting defence personnel who have not had a response to conventional treatments.
The investigation, coordinated by Cannabis Access Clinics, will run over the next 12 months.
Lead researcher Dr. Sharron Davis said traditional treatments did not really work for PTSD.
“It can present itself in lots of different ways, so it’s very difficult to find a treatment that is going to treat all of the symptoms of PTSD,” Dr. Davis said.
The study will see individuals prescribed a baseline dose of the oil that uses the non-psychoactive part of medicinal cannabis, referred to as CBD.
The project is being carried out in conjunction with BOD Australia, a global health and wellness business.
BOD Australia spokesperson Jo Patterson said participants might start with a dose of 5 millilitres.
“They might be on the product for up to five weeks — obviously it’s an observational trial, so they’ll assess the benefits that the product is offering the patient,” Ms Patterson said, adding that it was difficult to anticipate if the product would be available for mainstream purchase in future, but said it could be at least five years, depending on the results of the trial.
Dr Davis said she hoped the product would eventually become a freely available supplement like olive leaf oil.